Last updated: October 12, 2026
Lanthanum carbonate is a mature phosphate binder with limited remaining originator exclusivity and established generic competition. Commercial value is concentrated in formulation differentiation: palatability, tablet size, dosing convenience, powder delivery, manufacturing yield, and access to low-cost excipient systems. The most attractive opportunities are sugar-free chewables, orally administered granules or powders, high-load tablets, and region-specific products for patients who cannot swallow conventional tablets.
What is the FDA status of lanthanum carbonate?
Lanthanum carbonate is an FDA-approved oral phosphate binder marketed originally as Fosrenol. The product is indicated to reduce serum phosphate in patients with end-stage renal disease and in patients with chronic kidney disease receiving dialysis.[1]
| Item |
Status |
| Active ingredient |
Lanthanum carbonate |
| Original brand |
Fosrenol |
| Original sponsor |
Shire Pharmaceuticals |
| Current originator ownership history |
Shire acquired by Takeda in 2019 |
| FDA application |
NDA 021468 |
| Dosage forms |
Chewable tablets; oral powder |
| Primary use |
Phosphate control in chronic kidney disease |
| Regulatory category |
Small-molecule drug |
| Biosimilar pathway |
Not applicable |
| Generic pathway |
Abbreviated New Drug Application |
| Administration |
Oral, with or immediately after meals |
Lanthanum carbonate is practically insoluble in water. The drug acts locally in the gastrointestinal tract by binding dietary phosphate. Systemic absorption is low, which supports a formulation strategy focused on gastrointestinal dispersion, dosing with meals, taste control, and mechanical disintegration rather than rapid systemic release.[1]
What formulations are protected by lanthanum carbonate patents?
The commercial formulation has historically relied on several product attributes:
- High lanthanum carbonate loading.
- Chewable-tablet delivery.
- Oral powder delivery.
- Flavored and sweetened dosage forms.
- Dosing flexibility across multiple tablet strengths.
The original patent estate covered lanthanum-based phosphate-binding compositions, pharmaceutical preparations, and therapeutic use. The core Fosrenol exclusivity period has expired, and generic products are available in the United States. Any current patent assessment should distinguish expired composition and formulation patents from later patents covering manufacturing processes, specific excipient combinations, packaging, or alternative dosage forms.
What excipient functions matter most?
Lanthanum carbonate creates unusual excipient constraints because the active ingredient is dense, poorly soluble, administered in gram-level quantities, and used in a chewable product.
| Excipient function |
Strategic objective |
Relevant excipient classes |
| Binder |
Maintain tablet integrity during handling |
Povidone, copovidone, pregelatinized starch, microcrystalline cellulose |
| Filler |
Adjust tablet mass and mouthfeel |
Mannitol, sorbitol, xylitol, microcrystalline cellulose |
| Sweetener |
Reduce mineral and chalky taste |
Sucralose, acesulfame potassium, aspartame, saccharin |
| Flavor |
Improve adherence |
Citrus, berry, vanilla, mint, mixed fruit |
| Disintegrant |
Support rapid breakup after chewing or swallowing |
Crospovidone, croscarmellose sodium, sodium starch glycolate |
| Lubricant |
Improve compression and ejection |
Magnesium stearate, stearic acid, sodium stearyl fumarate |
| Glidant |
Improve powder flow |
Colloidal silicon dioxide |
| Moisture control |
Protect stability and processability |
Desiccants, moisture-barrier packaging, low-moisture excipients |
High levels of calcium-containing excipients should be evaluated carefully. Calcium salts can create formulation complexity because the product is administered for phosphate control and because mineral excipients may alter tablet density, taste, or phosphate-binding performance.
How should an excipient strategy be designed for lanthanum carbonate?
The preferred strategy is to treat the product as a high-dose, taste-sensitive chewable rather than as a conventional immediate-release tablet.
High-load chewable tablets
A high-load tablet can reduce pill burden, but the resulting unit may become large, hard, gritty, or difficult to chew. The formulation objective is not maximum active loading alone. It is the lowest acceptable tablet count without creating unacceptable mouthfeel.
A practical development sequence is:
- Establish the minimum excipient level required for compression.
- Compare direct compression with dry granulation.
- Measure tablet hardness, friability, chewability, and dispersion time.
- Evaluate particle-size distribution and segregation risk.
- Test taste after realistic chewing, not only after aqueous dissolution.
- Assess compression tooling wear caused by dense mineral material.
Mannitol is attractive for chewables because it provides a cooling sensation and relatively clean mouthfeel. Sorbitol can improve compressibility but increases hygroscopicity. Microcrystalline cellulose supports tablet structure but can create a dry or fibrous mouthfeel at high levels. Polyols also require gastrointestinal-tolerance testing.
Powder and granule formulations
Oral powder can address patients who cannot chew large tablets. It may also reduce compression-related manufacturing costs. The primary risks are dusting, segregation, inaccurate dosing, poor reconstitution, and taste exposure.
A commercial powder should be evaluated in:
- Sachets for single-meal dosing.
- Multi-dose bottles with a calibrated scoop.
- Sprinkle formulations for soft food.
- Granules with reduced dust generation.
- Unit-dose packets for dialysis centers and institutional use.
Powder products can create differentiated intellectual property around granule size, coating, moisture protection, dose uniformity, and taste masking. These claims are more defensible when tied to measurable performance outcomes rather than generic excipient selection.
Taste-masking systems
Lanthanum carbonate has a mineral taste and may leave a chalky sensation. Taste masking is therefore a central commercial issue.
Potential approaches include:
- Flavored polyol matrices.
- Coated particles or granules.
- Ion-exchange or polymeric taste-masking systems.
- Multiparticulate dosage forms.
- Sweetener and acidulant combinations.
- Encapsulation that delays release in the oral cavity.
Coating must not materially impair phosphate-binding performance after the product reaches the gastrointestinal tract. Coating polymers also increase tablet mass and may reduce the active-load advantage.
What commercial opportunities exist for lanthanum carbonate?
The strongest opportunities involve patient convenience and manufacturing economics rather than new clinical positioning.
Smaller-tablet and lower-pill-burden products
Lanthanum carbonate is often administered in multiple daily doses with meals. A product that delivers the same prescribed dose with fewer units may compete on adherence and convenience. The tradeoff is a larger individual tablet and potentially poorer chewability.
A differentiated product can target:
- Higher-strength chewable tablets.
- Scored tablets where technically feasible.
- Better taste at equivalent active loading.
- Lower tablet mass through optimized granulation.
- Combination packaging aligned with meal schedules.
Sugar-free and diabetic-friendly products
Chronic kidney disease populations have high rates of diabetes and metabolic comorbidity. Sugar-free formulations using mannitol, xylitol, sucralose, or high-intensity sweeteners may provide a commercially relevant distinction.
The formulation must control:
- Polyol-related gastrointestinal effects.
- Hygroscopicity.
- Sweetener stability.
- Flavor persistence.
- Labeling requirements for sugar alcohol content.
Oral powder for swallowing-impaired patients
A powder or granule product could address patients who cannot chew or swallow large tablets. The product would compete against other phosphate binders, including sevelamer, sucroferric oxyhydroxide, calcium-based binders, and ferric citrate.
The strongest product profile would combine:
- Single-dose meal packets.
- Low dusting.
- Rapid dispersion in soft food.
- Minimal taste exposure.
- Clear instructions for administration with meals.
- Packaging suitable for dialysis-center dispensing.
Regional and institutional products
Generic lanthanum carbonate may be commercially attractive in markets where dialysis treatment is expanding and branded access is limited. Opportunities include:
- Private-label supply.
- Hospital and dialysis-center contracts.
- Local-language packaging.
- Lower-cost bottle or blister configurations.
- Export products using regionally available excipients.
Excipients must comply with local pharmacopeial standards and regulatory requirements. A formulation dependent on specialized coated particles or proprietary taste-masking materials may increase supply-chain risk in emerging markets.
When did lanthanum carbonate lose exclusivity?
The originator’s core exclusivity has ended. Fosrenol was approved in the United States in 2004, and the principal patent and regulatory exclusivity period no longer prevents generic entry.[1][2]
| Exclusivity element |
Commercial position |
| FDA approval |
2004 |
| New chemical entity exclusivity |
Expired |
| Core composition and use patents |
Expired or no longer sufficient to block ordinary generic entry |
| Generic competition |
Established |
| Current differentiation |
Formulation, price, supply, packaging, and regional access |
The exact Orange Book listing and expiration status should be assessed by dosage form and strength because listed patents can differ between chewable tablets and oral powder products.[2]
What is the Orange Book status of Fosrenol and generic lanthanum carbonate?
The Orange Book identifies approved reference and generic products and records patents submitted by the NDA holder.[2] Lanthanum carbonate is not a biologic, so biosimilar substitution rules do not apply. Generic applicants generally use the ANDA pathway and must demonstrate pharmaceutical equivalence and bioequivalence or satisfy the applicable FDA requirements for the dosage form.
Relevant regulatory issues include:
- Active-ingredient equivalence.
- Strength and dosage-form equivalence.
- Dissolution or performance testing appropriate to a locally acting drug.
- Uniformity of high-dose tablets.
- Taste and chewability considerations where they affect administration.
- Labeling consistency with the reference product.
- Impurity and elemental-risk controls.
Because lanthanum is a metal-containing active ingredient, analytical control of elemental impurities, assay, content uniformity, and degradation-related species is important. ICH Q3D principles may be relevant to the overall elemental-impurity assessment.[3]
Are there Paragraph IV challenges to Fosrenol?
Generic lanthanum carbonate competition has developed through the ANDA pathway after expiration of the core originator exclusivity. Paragraph IV litigation is most relevant when an ANDA applicant certifies that an Orange Book-listed patent is invalid, unenforceable, or not infringed.
The commercial significance of a Paragraph IV case depends on:
- Whether the challenged patent remains listed.
- Whether the patent covers the proposed strength or dosage form.
- Whether a 30-month stay is triggered.
- Whether the product has a first-filer advantage.
- Whether the litigation concerns a commercially important formulation rather than an obsolete product configuration.
No biosimilar litigation framework applies because lanthanum carbonate is a synthetic small-molecule drug.
What patent litigation and settlement issues affect lanthanum carbonate?
The principal litigation risk is historical and formulation-specific. Once core patents expire, later disputes generally center on narrower claims, including:
- Specific excipient ratios.
- Granulation conditions.
- Taste-masked particles.
- Coated granules.
- Powder dosage forms.
- Packaging and moisture-control systems.
- Manufacturing processes that improve content uniformity.
Settlement agreements in generic litigation can affect launch timing, authorized-generic strategy, and market share. A settlement that permits entry before full patent expiry can reduce expected revenue for the originator while accelerating price erosion after launch.
For investment or licensing analysis, a patent family should be evaluated claim by claim. Broad claims to lanthanum carbonate as a phosphate binder have limited blocking value after expiration. Narrow process and formulation claims may retain value only if they are difficult to design around and linked to an approved, commercially preferred product.
How strong is the lanthanum carbonate patent estate?
The estate is commercially weak as a broad blocking platform because the original product has been available for many years and generic entry is established. Its remaining value lies in narrow formulation improvements.
| Patent category |
Strategic strength |
| Basic lanthanum carbonate composition |
Low after expiration |
| General phosphate-binding use |
Low after expiration |
| Chewable-tablet concept |
Low to moderate, depending on claim scope and expiry |
| Specific taste-masking system |
Moderate if clinically or technically necessary |
| High-load manufacturing process |
Moderate if difficult to design around |
| Oral powder and granule technology |
Moderate |
| Packaging and moisture protection |
Low to moderate |
| New combination product |
Potentially higher, but requires clinical and regulatory support |
A new patent filing based only on selecting a conventional sweetener or lubricant would likely face novelty and obviousness challenges. Stronger protection would require a defined formulation architecture with reproducible technical benefits, such as improved chewability at a specified active load, reduced dose variability, or preservation of phosphate-binding activity after taste masking.
How does lanthanum carbonate compare with competing phosphate binders?
| Product |
Active ingredient |
Key formulation issue |
Commercial implication |
| Fosrenol and generics |
Lanthanum carbonate |
Mineral taste, high dose, chewability |
Formulation and price competition |
| Renvela and generics |
Sevelamer carbonate/hydrochloride |
Large pill burden, powder options |
Established generic competition |
| Velphoro |
Sucroferric oxyhydroxide |
Chewability and iron-related taste |
Branded differentiation |
| Auryxia |
Ferric citrate |
Tablet burden and iron exposure |
Differentiated clinical positioning |
| Calcium acetate |
Calcium acetate |
Calcium load and tablet count |
Low-cost alternative |
Lanthanum carbonate’s main weakness is administration burden. Its main product-development advantage is local gastrointestinal activity without the calcium load associated with calcium-based binders. A successful reformulation must improve convenience without sacrificing phosphate-binding performance.
What generic launch risks exist?
Generic launch risk is high for undifferentiated tablets because the market is mature and price-sensitive. Key risks include:
- Rapid price erosion after multiple ANDA approvals.
- Limited payer preference for one generic supplier.
- Manufacturing variability in high-dose chewable tablets.
- Taste differences that reduce adherence.
- Limited profitability after wholesaler and payer discounts.
- Dependence on a small number of approved manufacturing sites.
- Commodity-excipient and packaging-cost inflation.
A differentiated powder, granule, or high-load product may reduce direct price comparison, but it requires separate regulatory, manufacturing, and commercial investment.
What revenue exposure remains for the originator?
Fosrenol’s revenue exposure is materially lower than during the branded exclusivity period because generic lanthanum carbonate is available. Public company reporting generally does not provide a standalone current revenue figure for Fosrenol after portfolio changes and generic erosion. The remaining commercial value is more likely to arise from legacy supply, licensing, authorized-generic arrangements, or regional distribution than from protected branded pricing.
Key Takeaways
- Lanthanum carbonate is a mature, genericized phosphate binder.
- The strongest commercial opportunity is formulation improvement, not broad composition patenting.
- Chewable tablets require careful control of taste, tablet mass, hardness, and active loading.
- Oral powders and granules offer the clearest route to differentiation for swallowing-impaired patients.
- Sugar-free, low-dusting, meal-aligned products may support premium positioning.
- The broad originator patent estate has limited blocking power after expiration.
- Narrow patents covering taste masking, granulation, moisture control, and dose uniformity may retain commercial value.
- Biosimilar risk is irrelevant because lanthanum carbonate is a small-molecule drug.
- Generic competition creates substantial price and supply-chain pressure.
- Any new product should be designed around adherence, dose burden, and manufacturing economics.
FAQs
Can lanthanum carbonate be formulated as a capsule?
A capsule is technically possible, but it may be commercially unattractive because lanthanum carbonate requires a relatively high dose. A capsule product could create excessive unit counts and would not provide the chewability advantage of the established dosage form.
Which excipient is best for improving lanthanum carbonate taste?
No single excipient is universally optimal. Mannitol, intense sweeteners, flavors, and coated-particle technologies should be screened together because mineral taste depends on particle size, oral residence time, compression behavior, and release from the dosage form.
Is lanthanum carbonate suitable for an orally disintegrating tablet?
An orally disintegrating tablet is challenging because of the high dose and dense mineral load. A multiparticulate powder or rapidly dispersible granule may provide a more practical alternative.
Can a new lanthanum carbonate product obtain composition-of-matter protection?
A conventional lanthanum carbonate tablet is unlikely to support broad composition-of-matter protection. Patent value would more likely come from a specific excipient architecture, particle coating, manufacturing process, or dosage form with demonstrated technical advantages.
What is the most defensible commercial niche for lanthanum carbonate?
The most defensible niche is a palatable, sugar-free, low-dust oral powder or granule designed for patients with swallowing limitations and administered in single-meal doses.
References
- U.S. Food and Drug Administration. (2004). Fosrenol (lanthanum carbonate) prescribing information.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- International Council for Harmonisation. (2014). ICH Q3D: Guideline for elemental impurities.
- U.S. Pharmacopeial Convention. (2023). United States Pharmacopeia and National Formulary.
- Takeda Pharmaceutical Company Limited. (2019). Annual report and product portfolio disclosures.
